Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...
New characters, content, and goodies; we’ve got exclusive insight about Reverse: 1999 Version 1.5 Phase 2 directly from the developers! Editorial Note: Talk Android may contain affiliate links on some ...
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies ...
REVERSE-IT is PhaseBio’s ongoing pivotal Phase 3 trial of its lead product bentracimab, which is designed to study the reversal of the antiplatelet effects of ticagrelor in patients who present either ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results